However, mutations (such as T315I) in the BCR-ABL gene were revealed to be the most common mechanism behind imatinib resistance, and they associate with an advanced disease state (accelerated or blast-phase CML). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.